Experienced in Undifferentiated Pleomorphic Sarcoma

Dr. Justin N. Bottsford-Miller

Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Bozeman Health Deaconess Hospital
905 Highland Blvd, Suite 4500, 
Bozeman, MT 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Undifferentiated Pleomorphic Sarcoma
Bozeman Health Deaconess Hospital
905 Highland Blvd, Suite 4500, 
Bozeman, MT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Justin Bottsford-Miller is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Bozeman, Montana. Dr. Bottsford-Miller is rated as an Experienced provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, Hernia Surgery, and Oophorectomy. Dr. Bottsford-Miller is currently accepting new patients.

His clinical research consists of co-authoring 33 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Obstetrics and Gynecology
Oncology
Licenses
Obstetrics & Gynecology in MT
Hospital Affiliations
Bozeman Health Deaconess Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Network Health
  • HMO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
PacificSource
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

BOZEMAN HEALTH DEACONESS HOSPITAL
905 Highland Blvd, Suite 4500, Bozeman, MT 59715

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Select Solid Tumors
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Select Solid Tumors
Enrollment Status: Recruiting
Publish Date: March 26, 2025
Intervention Type: Biological
Study Drugs: VV1, Cemiplimab
Study Phase: Phase 2
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Bevacizumab, Pembrolizumab, Carboplatin
Study Phase: Phase 1/Phase 2
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 02, 2025
Intervention Type: Drug, Biological
Study Drugs: GEN-1, Carboplatin, Paclitaxel
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)
A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)
Enrollment Status: Completed
Publish Date: April 05, 2023
Intervention Type: Drug, Biological
Study Drugs: Vigil Tumor Cells, Atezolizumab
Study Phase: Phase 2
View 5 Less Clinical Trials

33 Total Publications

Multi-Institutional Study of Referral Patterns for Gynecologic Oncology Consultation.
Multi-Institutional Study of Referral Patterns for Gynecologic Oncology Consultation.
Journal: JCO oncology practice
Published: May 22, 2024
Similar Doctors
Experienced in Undifferentiated Pleomorphic Sarcoma
Dr. Kenneth F. May
Oncology
Experienced in Undifferentiated Pleomorphic Sarcoma
Dr. Kenneth F. May
Oncology

Bozeman Health Deaconess Hospital

931 Highland Blvd, Suite 3130, 
Bozeman, MT 
 (0.1 miles away)
406-414-5070
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kenneth May is an Oncologist in Bozeman, Montana. Dr. May is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Neuroendocrine Tumor, Angiosarcoma, Inflammatory Breast Cancer, and Large-Cell Immunoblastic Lymphoma. Dr. May is currently accepting new patients.

Experienced in Undifferentiated Pleomorphic Sarcoma
Dr. Justin D. Thomas
Oncology
Experienced in Undifferentiated Pleomorphic Sarcoma
Dr. Justin D. Thomas
Oncology

Bozeman Health Deaconess Hospital

931 Highland Blvd, Suite 3130, 
Bozeman, MT 
 (0.1 miles away)
406-414-5070
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Justin Thomas is an Oncologist in Bozeman, Montana. Dr. Thomas is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Appendix Cancer, Neuroendocrine Tumor, Familial Colorectal Cancer, and Lynch Syndrome. Dr. Thomas is currently accepting new patients.

Experienced in Undifferentiated Pleomorphic Sarcoma
Dr. Dhimant R. Patel
Hematology Oncology | Hematology | Oncology
Experienced in Undifferentiated Pleomorphic Sarcoma
Dr. Dhimant R. Patel
Hematology Oncology | Hematology | Oncology

Bozeman Health Deaconess Hospital

931 Highland Blvd, Suite 3130, 
Bozeman, MT 
 (0.1 miles away)
406-414-5070
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Dhimant Patel is a Hematologist Oncology specialist and a Hematologist in Bozeman, Montana. Dr. Patel is rated as an Experienced provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Acute Hepatic Porphyria (AHP), Porphyria, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL). Dr. Patel is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bottsford-Miller's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 8 Advanced Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile